LIM kinasemodulating agents for neurofibromatoses therapy and methods for screening for same

摘要

Disclosed herein are methods of treating a patient at risk of developing or having a neurofibromatosis or a sporadic schwannoma. In exemplary embodiments, the method involves administering to a subject in need an effective amount of a LIMK modulating agent. Also disclosed are compounds newly identified to be inhibitors of Merlin-null Schwann cell proliferation and/or survival.

主权项

1. A method for treating a neurofibromatosis in a subject, the method comprising administering to the subject an effective amount of a LIMK modulating agent, wherein the LIMK modulating agent specifically inhibits activity of LIMK-1 (SEQ ID NO. 1), wherein the neurofibromatosis comprises a tumor of Schwann cell origin.